Calcium Gluconate Patent Expiration
Calcium Gluconate is used for treating high blood pressure and heart failure. It was first introduced by Fresenius Kabi Usa Llc
Calcium Gluconate Patents
Given below is the list of patents protecting Calcium Gluconate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Calcium Gluconate In Sodium Chloride | US10130646 | Calcium gluconate solutions in flexible containers | Jul 25, 2037 | Fresenius Kabi Usa |
| Calcium Gluconate In Sodium Chloride | US10130646 | Calcium gluconate solutions in flexible containers | Jul 25, 2037 | Hq Spclt Pharma |
| Calcium Gluconate In Sodium Chloride | US10342813 | Calcium gluconate solutions in flexible containers | Jul 25, 2037 | Hq Spclt Pharma |
Calcium Gluconate's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Calcium Gluconate:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| CAlcium and VAsopressin Following Injury Early Resuscitation (CAVALIER) Trial | Jason Sperry | NA |
RECRUITING
(Sep 1, 2026)
| PHASE2 |
| The Efficacy and Safety of Narlumosbart in Combination With Stereotactic Body Radiation Therapy to Improve the Efficacy of First-line Chemotherapy Combined With Immunotherapy in Patients With Bone Metastases From Advanced Non-small Cell Lung Cancer | Fudan University | NA |
RECRUITING
(Sep 1, 2026)
| PHASE2 |
| Prophylactic Intravenous Calcium Gluconate to Decrease Blood Loss at Time of Cesarean Delivery in Pregnant Patients at High Risk for Uterine Atony | University of Michigan | NA |
RECRUITING
(Jul 1, 2026)
| PHASE2 |
| Calcium Electroporation for Urinary Bladder Tumors: A First-in-Human Feasibility, Safety, and Early Response Trial | Juan Luis Vásquez | NA |
NOT YET RECRUITING
(Apr 1, 2026)
| PHASE1 |